Provider review
He & She MD Review: A Quiet Claim and Prices That Disagree
He & She MD is one of the few compounded GLP-1 sellers that does not borrow a trial result to sell a product. Its single outcome claim is footnoted to its own self-reported user data, and it says so. What it does not do is price consistently. Its plans page sells semaglutide at $199 month to month and $99 a month on a year paid up front, while the homepage cards and their own footnotes still quote a different, six-month offer.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit He & She MDOf He & She MD’s 4 dated product claims documented below, 3 are consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
One of the few sellers here that does not borrow a trial result to sell a compounded drug — and one whose prices need reading twice, because its homepage cards, their footnotes and its plans page each quote a different offer.
Worth trusting if
- You want a compounded GLP-1 from a company that does not quote trial percentages it has no right to
- You will prepay twelve months, which is where its genuinely low prices are
- You read footnotes before you buy
Be skeptical if
- You want to know which pharmacy fills your prescription, or which clinician prescribes it
- You want a certificate of analysis, or any published testing at all
- You want the homepage price to be the price you pay — its cards and their own footnotes disagree
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at He & She MD
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Semaglutide Injection — $199 a month billed monthly, falling to $149 a month on three months ($447), $139 on six ($834) and $99 on a year paid up front ($1,188). The homepage card reads “$99/mo to start”, but its footnote still describes a six-month offer at “$139/month”.
- Tirzepatide Injection — $299 a month billed monthly, falling to $209 a month on three months ($627), $199 on six ($1,194) and $159 on a year paid up front ($1,908). The homepage card reads “$159/mo to start”, while its footnote still quotes a six-month offer renewing at “$1,734”.
- Semaglutide Oral — $1,194 for the first six months, then $1,434 per six months — $239 a month, and $2,868 a year.
- Tirzepatide Oral — $269 a month on a 12-month purchase, $289 on six months, $309 on three and $339 on a single month, from the cost table on the product page.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
4
Products with human evidence
For the advertised use, out of 4 products reviewed here. The evidence concerns the molecule, not He & She MD's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from He & She MD’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Semaglutide InjectionSemaglutide · Compounded (503A)Claim matches the trials
“Limited Time Offer: Injectable Semaglutide just $99/month. […] GLP-1 Platinum Program Semagluide (Injection). A personalized GLP-1 injectable program designed for effective weight loss and long term success.* […] 15-25 Ibs Average weight loss in 12 weeks⁴ […] Medications included in the GLP-1 Program are produced in USP-compliant, state-regulated pharmacies but not reviewed by the FDA for safety, efficacy, or quality.”
Read on the He & She MD site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — roughly 14.9% mean weight loss from baseline against 2.4% on placebo.
He & She MD makes almost no efficacy claim for this product, which is why the verdict is what it is. There is no borrowed trial percentage on the weight-loss pages at all. The one outcome figure on the site — "15-25 Ibs Average weight loss in 12 weeks" — carries footnote 4, which attributes it to "a retrospective study of self-reported data of pounds lost for active versus passive users" of its own program. That is uncontrolled, self-reported, and the company says so in the footnote rather than dressing it as a trial. It also states, unprompted, that its medications are "not reviewed by the FDA for safety, efficacy, or quality". Semaglutide itself has phase 3 weight-loss evidence, and nothing on this site overstates it. The one place the site does overreach is regulatory rather than clinical: its feature list claims "FDA-regulated pharmacies", which contradicts its own disclaimer two screens away.1
Tirzepatide InjectionTirzepatide · Compounded (503A)Claim matches the trials
“GLP-1 Platinum Program Tirzepatide (Injectable). A personalized GLP-1 injectable program designed for sustainable weight loss and long term success.* […] $189 $159/mo to start¹”
Read on the He & She MD site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tirzepatide over 72 weeks; roughly 20–22% mean weight reduction at the highest tolerated dose, with lifestyle intervention in every arm.
The tirzepatide card claims “sustainable weight loss and long term success” and no number, so there is no trial figure to check it against and nothing here overstates the evidence. Tirzepatide has phase 3 weight-loss data of its own. What the card does obscure is the money rather than the medicine: “$159/mo to start” against a struck-through $189 reads as a standing rate, while footnote 1 still describes a six-month offer renewing at “$1,734”, and the plans page charges $299 month to month.2
Semaglutide OralSemaglutide · Compounded (503A)Claim matches the trials
“GLP-1 Platinum Program Semagluide (oral). A personalized GLP-1 dose oral program designed for weight loss and long term success.* […] $239 $209/mo to start³”
Read on the He & She MD site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. The phase 3 weight-loss evidence for semaglutide is for the once-weekly SUBCUTANEOUS 2.4 mg dose. It is not evidence for a compounded oral preparation at an unstated dose.
As of August 2026 the site publishes no trial, no dose and no bioavailability figure for its oral semaglutide, and names no study of the oral preparation it sells. Semaglutide's own oral evidence base (the PIONEER program) tested a specific tablet formulation with an absorption enhancer, which a compounded oral preparation is not.
Again, no efficacy claim is made for the oral route — the card promises “weight loss and long term success” and nothing quantified — so there is nothing that overstates a trial. But the absence cuts both ways and a reader should see it: the phase 3 semaglutide weight-loss data is for a weekly subcutaneous injection, the approved oral semaglutide product is a specific tablet built around an absorption enhancer, and a compounded oral preparation is neither of those things. The site states no dose, no formulation and no bioavailability for what it is selling. It also costs more per year than the injection, at $2,868 against $1,188 for a year of the injection paid up front.1
Tirzepatide OralTirzepatide · Compounded (503A)Claim reaches past the trials
“GLP-1 Platinum Program Tirzepatide (Oral). A personalized GLP-1 dose oral program designed for weight loss and long term success.* $299 $269/mo to start⁴ […] Tirzepatide Oral. Starting at $269 /month* […] * Price for purchase of 12 month supply. […] Longevity & Vitality Support. Promotes overall well-being and vitality. Tirzepatide’s effects not only support physical health but also promote overall well-being and vitality, enhancing life quality and longevity through balanced metabolic health.”
Read on the He & She MD site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. The phase 3 weight-loss evidence for tirzepatide is for a once-weekly SUBCUTANEOUS injection. It is not evidence for a compounded daily tablet at an unstated dose.
As of September 2026 the site publishes no trial, no dose and no absorption figure for its oral tirzepatide, and names no study of the tablet it sells. No oral form of tirzepatide is FDA-approved; every registered weight-loss trial of the molecule used the weekly injection.
The homepage card, like its siblings, promises “weight loss and long term success” and no number. The product page goes further. Its “Longevity & Vitality Support” panel says tirzepatide enhances “life quality and longevity”, and no trial of tirzepatide in any form has measured longevity. The route matters too. The phase 3 weight-loss results for tirzepatide come from a weekly injection, no tablet form of the molecule is approved, and the site gives no dose, formulation or absorption figure for the daily tablet it sells. The card's “to start⁴” points to the footnote about self-reported user data, not to a price term. The product page gives the real one: $269 a month is the rate on a 12-month purchase.2
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named anywhere on their site. The FAQ carries the question “Who are your pharmacy partners?” and the answer is behind an accordion that names no company; the medication disclaimer refers only to “USP-compliant, state-regulated pharmacies”. Nor is any prescriber, medical director or clinician network named — the “Who are your medical partners?” question is answered the same way. A reader cannot check a license number, because no licensee is identified.
Read on the He & She MD site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis is published, offered on request, or mentioned. The site's quality claim is the phrase “FDA-regulated pharmacies” in its feature list — which is not a testing disclosure and is contradicted by the company's own medication disclaimer, stating the products are “not reviewed by the FDA for safety, efficacy, or quality”. Compounded preparations are made by pharmacies licensed and inspected by state boards; FDA does not review them.
Read on the He & She MD site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
The site says it ships nationwide and answers “What states do you ship to?” in its FAQ without publishing a list or a set of exclusions. No state-by-state page or list of jurisdictions is published anywhere on their site, so the coverage claim cannot be checked against anything.
Read the full licensing claim
Licensed U.S. Telehealth Platform
Read on the He & She MD site, August 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
We did this ourselves
What happens when you sign up with He & She MD
We went through He & She MD’s signup ourselves in August 2026: the steps, when a price first appears, and what it asks you for. We stopped at checkout, so nothing here is a prescription or a medical result.
- Press See If You Qualify from the offer banner, which opens the online visit.
- Give your weight and height. A BMI is calculated as you type, and the screen states the thresholds first: over 25 if you have never taken a GLP-1, over 20 if you have.
- Give a goal weight, then your date of birth, then the sex you were assigned at birth.
- Give a mobile number and zip code, with the SMS consent paragraph attached to the same box.
- Answer the screening: disqualifying conditions, every medication you take, the diabetes medicines that rule you out, gastric bypass in the past six months, how you currently manage your weight, allergies, and which GLP-1 brands you are allergic to.
- Give an email, then create an account with a password. That is where we stopped.
- Not one figure is shown inside the online visit. Every figure in this review sits on the marketing pages you pass through first, and the eleven screens never mention cost.
- That matters more here than elsewhere. The banner that starts this flow quotes a promotional rate, and nothing in the visit restates the term before the account is created.
- The eligibility rule is published before you answer it. The first screen prints both BMI thresholds and computes yours live.
- The screening is more thorough than most of this category: a disqualifying-conditions list, a full medication list, a diabetes-medication list, a gastric bypass question and a GLP-1 allergy list.
- Two screens say plainly that a wrong answer ends it — "this may disqualify you from taking this medication", and "if you take any of these medications, you will not be eligible for this medication".
- The phone screen bundles verification consent with marketing consent. One checkbox covers verifying your number and receiving cart reminders, promotions and shipment notifications.
- The gate at the end is a password, not an emailed code, and it comes after the whole medical history rather than before it.
He & She MD support
Assessment
What holds up, and what does not
- It makes almost no efficacy claim. On a site selling compounded semaglutide and tirzepatide, the absence of a borrowed trial percentage is the single most unusual thing about it.
- Its one outcome figure is footnoted honestly to its own retrospective, self-reported user data rather than presented as a trial result.
- It states without being asked that its medications are “not reviewed by the FDA for safety, efficacy, or quality”.
Show 1 more
- The price does not rise as the dose is titrated upward.
- No pharmacy is named. No prescriber is named. No state license number is published for anyone in the chain.
- No certificate of analysis is published or offered, and no testing of any kind is described.
- “FDA-regulated pharmacies” appears in the feature list while the medication disclaimer says the opposite on the same site.
Show 5 more
- The homepage card says “$99/mo to start” while its own footnote still describes six months at “$139/month”; the plans page charges $199 month to month.
- Paying month to month costs $199 a month, about double the $99 a month of a year paid up front.
- The Terms of Service name no corporate entity and no address, and the platform is licensed from Bask Health Inc, so the company a customer is contracting with is not identified anywhere.
- Oral semaglutide is sold with no dose, no formulation and no bioavailability figure, and the phase 3 evidence for semaglutide weight loss is for a weekly injection.
- The oral tirzepatide page credits the drug with “enhancing life quality and longevity”, which no trial has measured, for a tablet form of tirzepatide that no trial has tested.
Verdict
The bottom line
Judged on claims, this is a better-behaved seller than most of this market: it does not quote a trial it has no right to, and it admits its products are not FDA-reviewed. Judged on what it discloses about the supply chain, it is among the thinnest — no pharmacy, no prescriber, no testing, no company name. Check the plans page before you buy anything, because the homepage cards and their footnotes disagree.
Opens He & She MD's website. A link is not a recommendation to take anything.
A company that does not borrow a trial
Most compounded GLP-1 sellers reviewed on this site quote a weight-loss percentage from a trial of the branded drug and let the reader assume it applies to the compounded preparation they are buying. He & She MD does not do this. Its weight-loss pages carry no trial percentage at all.
The single outcome figure anywhere on the site is "15-25 Ibs average weight loss in 12 weeks", and it is footnoted:
"Based on a retrospective study of self-reported data of pounds lost for active versus passive users who were offered the He & She MD program when being prescribed an early stage GLP-1."
That is uncontrolled, self-selected and self-reported, and every one of those weaknesses is visible in the sentence the company wrote. A retrospective comparison of "active versus passive users" of a program tells you about the kind of person who engages with an app, not about what the drug does. But it is presented as what it is.
It also states, in the fine print under its own product list, that medications in the program are "produced in USP-compliant, state-regulated pharmacies but not reviewed by the FDA for safety, efficacy, or quality." 1 2
Full analysis — 5 more sectionsThe one claim that does not hold · What is missing · Three places, three prices · The oral route · What this means if you are buying
The one claim that does not hold
Under "Why He & She MD", the first feature reads "FDA-regulated pharmacies".
That is not right, and the site's own disclaimer proves it knows better. Compounding pharmacies are licensed and inspected by state boards of pharmacy; FDA does not regulate the compounded preparations they make, which is exactly what "not reviewed by the FDA for safety, efficacy, or quality" says two screens away.
It is the same loose phrase the whole category reaches for, on a site that otherwise gets the distinction right.
What is missing
Everything about who actually fills the prescription.
No pharmacy is named. The FAQ asks "Who are your pharmacy partners?" and answers without naming one. No prescriber, medical director or clinician network is named either. No state license number is published for anyone. No certificate of analysis is published, offered on request, or mentioned at all.
For comparison, the best-disclosed company we've reviewed names two pharmacies, publishes a state board license number a reader can check independently, names its medical director, and acknowledges that a certificate of analysis exists. He & She MD publishes none of those four.
The Terms of Service do not name the company either. They introduce the operator as "He and She MD, and their respective affiliates", choose Delaware law, give no address and no corporate form — and state that using the service means "accepting use of Bask Health Inc's platform". The telehealth software is licensed from a third party, which is ordinary in this category. Not naming the contracting entity is not.
Three places, three prices
The plans page is the one to trust. Semaglutide injection is $199 a month billed monthly, $447 for three months, $834 for six and $1,188 for a year paid up front. Tirzepatide runs $299, $627, $1,194 and $1,908.
The homepage cards quote something else: "$99/mo to start" for semaglutide and "$159/mo to start" for tirzepatide, each against a struck-through price.
And the footnotes under those cards still describe the older six-month offer:
"For the first 6 months, you'll pay $139/month — a total savings of $360, nearly equal to 2 months free. After the first 6 months, the plan renews at the regular 6-month price of $1,194, equivalent to $199/month."
A card, its footnote and the plans page, all for one injection, and no two agree. The low figures belong to a year paid up front. Month to month, a year costs about double.
The oral route
Oral semaglutide is sold here with no dose, no formulation and no bioavailability figure.
That gap is worth naming, because the evidence a reader will have in mind does not travel to it. The phase 3 weight-loss data for semaglutide is for a once-weekly subcutaneous injection. 1 The approved oral semaglutide product is a specific tablet built around an absorption enhancer. A compounded oral preparation is neither, and nothing on this site says what it actually is.
Oral tirzepatide has the same gap, and one more claim on top. The homepage card reads "$269/mo to start". The product page shows what that is: the rate on a 12-month purchase, rising to $339 a month if you buy one month at a time. Every weight-loss trial of tirzepatide used a once-weekly injection, 2 and no tablet form of the molecule is approved. The page also says tirzepatide promotes "overall well-being and vitality, enhancing life quality and longevity". No trial of tirzepatide has measured longevity.
The oral routes are also the most expensive options on offer per year.
What this means if you are buying
If you want a compounded GLP-1 from a company that will not lie to you about what the trials showed, this one clears that bar more cleanly than most of this market — largely by declining to make the claim at all.
If you want to know who compounds it, who prescribes it, what is in the vial, or which company is taking your money, this site answers none of those questions.
And whichever you decide: read footnote 2 first. The number on the card is not the number you are committing to.
Questions
Frequently asked questions
Does He & She MD overstate what GLP-1s do?
No, and it is unusual in that. There is no borrowed trial percentage anywhere on its weight-loss pages. Its only outcome figure — 15-25 lbs in 12 weeks — is footnoted to its own retrospective look at self-reported data from active versus passive users of its program, which is uncontrolled and self-selected, and the footnote says so. It also states voluntarily that its medications are not reviewed by the FDA for safety, efficacy, or quality.
Does it publish a certificate of analysis?
No. It publishes none, offers none on request, and does not mention testing at all. Its only quality claim is the phrase “FDA-regulated pharmacies” in its feature list, which is not a testing disclosure — and which its own medication disclaimer contradicts.
Which pharmacy fills the prescription?
Unknown. The site's FAQ asks the question and answers it without naming a pharmacy, and the medication disclaimer refers only to “USP-compliant, state-regulated pharmacies”. No prescriber or clinician network is named either, and no state license number is published for anyone in the chain.
What does it actually cost?
It depends on the term. On the plans page, semaglutide injection is $199 a month billed monthly, $447 for three months, $834 for six and $1,188 for a year paid up front. Tirzepatide is $299 a month, $627, $1,194 or $1,908. The homepage cards quote lower "to start" figures, and their footnotes describe an older six-month offer, so go by the plans page. Oral semaglutide is sold on a six-month term renewing at $1,434. Oral tirzepatide runs from $339 a month bought one month at a time down to $269 a month on a 12-month purchase.
Compare
Others selling what He & She MD sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists He & She MD is on
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off He & She MD's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.